View Older Stories
-
Vertex (VRTX) Reiterated at Overweight by Cantor Fitzgerald; Crinetics Acquisition Announced
-
Canaccord Reiterates Hold Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) call put ratio 1 call to 1.8 puts into acquiring Crinetics
-
Crinetics soars on $10B acquisition by Vertex
-
Vertex signs LoI with the Pan-Canadian Pharmaceutical Alliance for alyftrek for the treatment of cystic fibrosis
-
FDA approves Casgevy gene therapy for sickle cell in children 2+
-
Leerink highlights drug demand rebound after Memorial Day
-
Vertex presents positive data for ALYFTREK in young cystic fibrosis patients
-
Vertex gets FDA acceptance for IgA nephropathy drug application
-
Truist Securities Assumes Vertex (VRTX) at Buy
-
BMO Capital Reiterates Market Perform Rating on Vertex (VRTX), 'positive steps'
-
Vertex secures German reimbursement for CASGEVY gene therapy
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX) Post Q1 Print
-
Vertex (VRTX) PT Lowered to $436 at Canaccord
-
Oppenheimer Reiterates Outperform Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $572 at Bernstein SocGen Group
-
Vertex Pharma (VRTX) Tops Q1 EPS by 14c, Misses on Revenue; Offers FY26 Revenue Guidance
-
U.S. Biotech stocks: Q1 earnings previews
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
These are the best biotech stocks to own in 2026: BofA
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
Vertex (VRTX) PT Lowered to $541 at RBC Capital
-
Halozyme licenses drug delivery technology to Vertex for $15 million
-
BMO Capital on Vertex (VRTX): 'Ivacaftor Related Label Updates Unlikely to Impact CF Franchise Strength'
-
BMO Capital on Vertex (VRTX): label updates weigh on shares, but risk is limited
-
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
-
RBC Capital on Vertex (VRTX): 'Recent Weakness Creates Buying Opportunity'
-
Vertex (VRTX) PT Raised to $520 at Argus
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
Vertex (VRTX) PT Raised to $525 at Truist Securities
-
Stifel Reiterates Hold Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Raised to $641 at H.C. Wainwright
-
Bernstein: 'We continue to recommend Vertex (VRTX) and see no reason to take profits'
-
Jefferies Starts Amgen (AMGN) at Hold
-
Jefferies Starts Vertex (VRTX) at Buy
-
Jefferies Starts Gilead Sciences (GILD) at Buy
-
Vertex (VRTX) PT Raised to $600 at Oppenheimer
-
Vertex (VRTX) PT Raised to $585 at Citi
-
Wolfe Research Reiterates Outperform Rating on Vertex (VRTX) following Ph3
-
BMO Capital Reiterates Outperform Rating on Vertex (VRTX) amid interim RAINIER data
-
After-hours movers: Hewlett Packard Enterprise, Yext, Vertex Pharma
-
Vertex (VRTX) PT Raised to $600 at BMO Capital
-
Vertex (VRTX) PT Raised to $590 at Cantor Fitzgerald
-
Oppenheimer Upgrades Vertex (VRTX) to Outperform
-
Vertex Pharma (VRTX) Misses Q4 EPS by 5c; offers guidance
-
Bernstein SocGen Group Reiterates Outperform Rating on Vertex (VRTX)
-
Barclays Starts Vertex (VRTX) at Overweight, 'bullish into 2026 readouts'
-
Vertex (VRTX) PT Raised to $530 at Evercore ISI
-
RBC Capital Upgrades Vertex (VRTX) to Outperform
-
Bernstein SocGen Group Upgrades Vertex (VRTX) to Outperform

